Study design and population

JK Joanna Kedra
RS Raphaele Seror
PD Philippe Dieudé
AC Arnaud Constantin
ET Eric Toussirot
EK Elias Kfoury
CM Charles Masson
DC Divi Cornec
JD Jean Jacques Dubost
LM Laurent Marguerie
SO Sebastien Ottaviani
FG Franck Grados
RB Rakiba Belkhir
OF Olivier Fain
PG Philippe Goupille
CS Christelle Sordet
BF Bruno Fautrel
PP Peggy Philippe
MP Muriel Piperno
BC Bernard Combe
OL Olivier Lambotte
CR Christophe Richez
JS Jérémie Sellam
TS Thomas Sené
GD Guillaume Denis
TL Thierry Lequerre
TL Thierry Lazure
XM Xavier Mariette
GN Gaetane Nocturne
ask Ask a question
Favorite

In this French multicentre case–control study, cases were adults (age ≥18 years) with RA fulfilling ACR-EULAR 2010 criteria in whom B-cell NHL or Hodgkin’s lymphoma developed after the diagnosis of RA. Exclusion criteria were T-cell lymphoma, a history of lymphoma before the RA diagnosis and a history of secondary Sjögren’s syndrome, given that this autoimmune condition is associated with increased risk of lymphoma.1 3 Cases were recruited following a call for observations mediated by the CRI-IMIDIATE network and among French Society of Rheumatology registries (AIR-PR, ORA, REGATE) and the Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort. The AIR-PR, ORA and REGATE registries and the ESPOIR cohort have been described in previous studies.17–20 Cases were excluded if the case report form was not sent to the investigating centre (Kremlin-Bicêtre Hospital).

Controls were drawn at random from the ESPOIR cohort among patients with RA fulfilling ACR-EULAR 2010 criteria who completed a 10-year follow-up. Cases and controls were matched on age (age at lymphoma diagnosis for cases and age at 10-year ESPOIR visit for controls). This variable was chosen because of its well-known association with risk of B-cell lymphoma in the overall population.21

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A